CPB2 and small cell lung carcinoma: In the external validation, the same-variant and significant-variant strategies were used to further verify seven plasma proteins identified in the primary analysis, demonstrating that CPB2, GSTM3, NTNG1, and FAM171B also had significant associations with the risk of SCLC (Figure 2).